1. Home
  2. TKNO vs OABI Comparison

TKNO vs OABI Comparison

Compare TKNO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$9.33

Market Cap

268.1M

Sector

Health Care

ML Signal

HOLD

Logo OmniAb Inc.

OABI

OmniAb Inc.

HOLD

Current Price

$4.80

Market Cap

294.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKNO
OABI
Founded
1996
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
268.1M
294.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
TKNO
OABI
Price
$9.33
$4.80
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $4.50
AVG Volume (30 Days)
201.7K
★ 1.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 43.86
6.56
EPS
N/A
★ N/A
Revenue
★ $40,520,000.00
$18,666,000.00
Revenue This Year
$8.27
$52.42
Revenue Next Year
$13.13
$64.69
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 7.35
N/A
52 Week Low
$1.91
$1.32
52 Week High
$9.41
$5.43

Technical Indicators

Market Signals
Indicator
TKNO
OABI
Relative Strength Index (RSI) 73.40 60.73
Support Level $4.87 $1.90
Resistance Level N/A $5.43
Average True Range (ATR) 0.47 0.25
MACD 0.17 -0.02
Stochastic Oscillator 80.13 72.40

Price Performance

Historical Comparison
TKNO
OABI

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.

About OABI OmniAb Inc.

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Share on Social Networks: